Jain Global’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jain Global’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,271	Closed	-$241K	–	1754
2026 Q1	$241K	Sell	4,271 -15,181	-78%	-$885K	﹤0.01%	1056
2025 Q4	$1.16M	Buy	+19,452	New	+$1.06M	0.01%	690
2025 Q2	–	Sell	-92,980	Closed	-$6.57M	–	1211
2025 Q1	$6.57M	Buy	92,980 +85,328	+1,115%	+$5.74M	0.08%	191
2024 Q4	$503K	Buy	+7,652	New	+$513K	0.02%	443

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Jain Global's BMRN Position: Q2 2026 in Review

Jain Global sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 4,271 shares — an estimated $241K sold.

Jain Global first reported a position in BMRN in Q4 2024 and held it in 4 quarters. The position peaked at $6.57M in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Jain Global reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Jain Global sold 4,271 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $241K.
Jain Global first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 4 quarters.
Jain Global's BioMarin Pharmaceuticals position peaked at $6.57M in Q1 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Jain Global's 13F filing for Q2 2026, filed 14 Aug 2026.